Tyra Biosciences (TYRA) Net Cash Flow (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Net Cash Flow came in at $7.6 million in Q1 2026, down 13.56% YoY from $8.8 million in Q1 2025, and down 50.97% on a QoQ basis from $15.4 million in Q4 2025.
Tyra Biosciences (TYRA) Net Cash Flow (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Net Cash Flow data on file, last reported at $7.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 13.56% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.8 million (up 89.74% YoY) and the FY2025 annual result came in at -$14.6 million, down 142.93% from the prior year.
- Net Cash Flow slipped to $7.6 million in Q1 2026, from $15.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $196.4 million in Q1 2024 to a low of -$157.6 million in Q4 2023.
- A 5-year average of -$12.7 million and a median of -$9.5 million in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 2164.34% in 2024, down 1567.48% in 2024.
- Tracing TYRA's Net Cash Flow over 5 years: stood at -$12.0 million in 2022, then plunged by 1213.94% to -$157.6 million in 2023, then surged by 92.43% to -$11.9 million in 2024, then surged by 229.43% to $15.4 million in 2025, then plunged by 50.97% to $7.6 million in 2026.
- The last three Net Cash Flow figures came in at $7.6 million (Q1 2026), $15.4 million (Q4 2025), and -$36.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | -11.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.12 Mn |
| Jun 30, 2026 | -11.12 Mn |
| Mar 31, 2026 | 7.57 Mn |
| Mar 31, 2026 | 7.57 Mn |
| Dec 31, 2025 | 15.44 Mn |
| Dec 31, 2025 | 15.44 Mn |
| Sep 30, 2025 | -36.54 Mn |
| Sep 30, 2025 | -36.54 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Mar 31, 2025 | 8.76 Mn |
| Mar 31, 2025 | 8.76 Mn |
| Dec 31, 2024 | -11.93 Mn |
| Dec 31, 2024 | -11.93 Mn |
| Sep 30, 2024 | 4.40 Mn |
| Sep 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | -154.88 Mn |
| Jun 30, 2024 | -154.88 Mn |
| Mar 31, 2024 | 196.36 Mn |
| Mar 31, 2024 | 196.36 Mn |